Aerovate Therapeutics Inc... (AVTE)
2.51
0.00 (0.00%)
At close: Apr 02, 2025, 3:59 PM
2.52
0.40%
After-hours: Apr 02, 2025, 04:37 PM EDT
0.00% (1D)
| Bid | 2.49 |
| Market Cap | 72.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.44 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -5.29 |
| Analyst | Hold |
| Ask | 2.95 |
| Volume | 37,892 |
| Avg. Volume (20D) | 140,378 |
| Open | 2.56 |
| Previous Close | 2.51 |
| Day's Range | 2.50 - 2.55 |
| 52-Week Range | 1.25 - 30.29 |
| Beta | 1.00 |
About AVTE
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 30
Stock Exchange NASDAQ
Ticker Symbol AVTE
Website https://aerovatetx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $2, which is a decrease of -20.32% from the latest price.
Stock Forecasts5 months ago
+11.87%
Aerovate Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
8 months ago
+8.07%
Aerovate Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
